Kezar Life Sciences Inc (KZR) - Net Assets
Based on the latest financial reports, Kezar Life Sciences Inc (KZR) has net assets worth $70.07 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($76.65 Million) and total liabilities ($6.57 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check how resilient are Kezar Life Sciences Inc's assets to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $70.07 Million |
| % of Total Assets | 91.42% |
| Annual Growth Rate | N/A |
| 5-Year Change | -64.41% |
| 10-Year Change | N/A |
| Growth Volatility | 44.94 |
Kezar Life Sciences Inc - Net Assets Trend (2016–2025)
This chart illustrates how Kezar Life Sciences Inc's net assets have evolved over time, based on quarterly financial data. Also explore total assets of Kezar Life Sciences Inc for the complete picture of this company's asset base.
Annual Net Assets for Kezar Life Sciences Inc (2016–2025)
The table below shows the annual net assets of Kezar Life Sciences Inc from 2016 to 2025. For live valuation and market cap data, see KZR company net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $70.07 Million | -40.07% |
| 2024-12-31 | $116.92 Million | -37.67% |
| 2023-12-31 | $187.57 Million | -30.50% |
| 2022-12-31 | $269.87 Million | +37.08% |
| 2021-12-31 | $196.88 Million | +39.65% |
| 2020-12-31 | $140.98 Million | +80.63% |
| 2019-12-31 | $78.05 Million | -28.26% |
| 2018-12-31 | $108.80 Million | +523.55% |
| 2017-12-31 | $-25.69 Million | -47.39% |
| 2016-12-31 | $-17.43 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Kezar Life Sciences Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 47302100000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $7.00K | 0.01% |
| Other Components | $560.60 Million | 800.02% |
| Total Equity | $70.07 Million | 100.00% |
Kezar Life Sciences Inc Competitors by Market Cap
The table below lists competitors of Kezar Life Sciences Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Introl S.A.
WAR:INL
|
$54.05 Million |
|
GP Global Power Ltd
TA:GPGB
|
$54.05 Million |
|
Kamat Hotels (I) Limited
NSE:KAMATHOTEL
|
$54.06 Million |
|
Purple Innovation Inc
NASDAQ:PRPL
|
$54.06 Million |
|
LondonMetric Property Plc
LSE:LMP
|
$54.03 Million |
|
An Phat Holdings JSC
VN:APH
|
$54.02 Million |
|
Sambu Const
KO:001470
|
$54.01 Million |
|
KWG Group Holdings Limited
F:KOU
|
$53.96 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Kezar Life Sciences Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 116,916,000 to 70,073,000, a change of -46,843,000 (-40.1%).
- Net loss of 56,033,000 reduced equity.
- New share issuances of 65,000 increased equity.
- Other comprehensive income increased equity by 162,000.
- Other factors increased equity by 8,963,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-56.03 Million | -79.96% |
| Share Issuances | $65.00K | +0.09% |
| Other Comprehensive Income | $162.00K | +0.23% |
| Other Changes | $8.96 Million | +12.79% |
| Total Change | $- | -40.07% |
Book Value vs Market Value Analysis
This analysis compares Kezar Life Sciences Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.77x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | $-1.34 | $7.33 | x |
| 2017-12-31 | $-1.97 | $7.33 | x |
| 2018-12-31 | $5.72 | $7.33 | x |
| 2019-12-31 | $4.09 | $7.33 | x |
| 2020-12-31 | $3.20 | $7.33 | x |
| 2021-12-31 | $3.73 | $7.33 | x |
| 2022-12-31 | $4.01 | $7.33 | x |
| 2023-12-31 | $2.59 | $7.33 | x |
| 2024-12-31 | $1.60 | $7.33 | x |
| 2025-12-31 | $9.58 | $7.33 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Kezar Life Sciences Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -79.96%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.09x
- Recent ROE (-79.96%) is below the historical average (-34.72%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | 0.00% | 0.00% | 0.00x | 0.00x | $-7.25 Million |
| 2017 | 0.00% | 0.00% | 0.00x | 0.00x | $-5.95 Million |
| 2018 | -21.29% | 0.00% | 0.00x | 1.05x | $-34.05 Million |
| 2019 | -40.40% | 0.00% | 0.00x | 1.15x | $-39.34 Million |
| 2020 | -27.66% | 0.00% | 0.00x | 1.08x | $-53.09 Million |
| 2021 | -27.75% | 0.00% | 0.00x | 1.11x | $-74.32 Million |
| 2022 | -24.20% | 0.00% | 0.00x | 1.11x | $-92.30 Million |
| 2023 | -54.31% | -1455.29% | 0.03x | 1.18x | $-120.63 Million |
| 2024 | -71.62% | 0.00% | 0.00x | 1.24x | $-95.43 Million |
| 2025 | -79.96% | 0.00% | 0.00x | 1.09x | $-63.04 Million |
Industry Comparison
This section compares Kezar Life Sciences Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $44,828,400
- Average return on equity (ROE) among peers: -124.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Kezar Life Sciences Inc (KZR) | $70.07 Million | 0.00% | 0.09x | $54.03 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $3.60 Million | -91.89% | 0.28x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $448.19K |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $88.00 Million | -44.09% | 0.34x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $80.00K | -31.70% | 0.38x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $23.36 Million | -97.44% | 0.37x | $3.74 Billion |
About Kezar Life Sciences Inc
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor for various indications, including lupus nephritis, dermatomyositis, and polymyo… Read more